Co-transplantation of multipotent mesenchymal stromal cells in allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis

Cytotherapy

Volumn 18, Issue 2, 2016, Pages 172-185

  Kallekleiv, Merete ^a,b   Larun, Lillebeth ^c   Bruserud, Øystein ^a,d   Hatfield, Kimberley Joanne ^d  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b BERGEN UNIVERSITY COLLEGE   (Norway)

^c NORWEGIAN KNOWLEDGE CENTRE FOR THE HEALTH SERVICES   (Norway)

^d UNIVERSITY OF BERGEN   (Norway)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Engraftment; Evidence based practice; Graft versus host disease; Multipotent mesenchymal stromal cells; Systematic review

Indexed keywords

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CLINICAL OUTCOME; CONTROLLED CLINICAL TRIAL (TOPIC); ENGRAFTMENT; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; MESENCHYMAL STROMA CELL; MESENCHYMAL STROMAL CELL TRANSPLANTATION; META ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; SYSTEMATIC REVIEW; THERAPY EFFECT; ADOLESCENT; ADULT; CHILD; CYTOLOGY; DISEASE FREE SURVIVAL; EPIDEMIOLOGY; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MIDDLE AGED; PRESCHOOL CHILD; PROCEDURES; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; TREATMENT OUTCOME;

EID: 84991327497     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2015.11.010     Document Type: Review

References (53)

1. [1] Bacigalupo, A., Mesenchymal stem cells and haematopoietic stem cell transplantation. Best Pract Res Clin Haematol 17 (2004), 387–399.
2. [2] Cahn, J.Y., Klein, J.P., Lee, S.J., Milpied, N., Blaise, D., Antin, J.H., et al. Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study. Blood 106 (2005), 1495–1500.
3. [3] Lee, S.J., Vogelsang, G., Gilman, A., Weisdorf, D.J., Pavletic, S., Antin, J.H., et al. A survey of diagnosis, management, and grading of chronic GVHD. Biol Blood Marrow Transplant 8 (2002), 32–39.
4. [4] Gratwohl, A., Brand, R., Frassoni, F., Rocha, V., Niederwieser, D., Reusser, P., et al. Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant 36 (2005), 757–769.
5. [5] Wingard, J.R., Majhail, N.S., Brazauskas, R., Wang, Z., Sobocinski, K.A., Jacobsohn, D., et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol 29 (2011), 2230–2239.
6. [6] Horwitz, E.M., Le Blanc, K., Dominici, M., Mueller, I., Slaper-Cortenbach, I., Marini, F.C., et al. Clarification of the nomenclature for MSC: the International Society for Cellular Therapy position statement. Cytotherapy 7 (2005), 393–395.
7. [7] Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F., Krause, D., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8 (2006), 315–317.
8. [8] Horwitz, E.M., Maziarz, R.T., Kebriaei, P., MSCs in hematopoietic cell transplantation. Biol Blood Marrow Transplant 17 (2011), S21–9.
9. [9] Angelopoulou, M., Novelli, E., Grove, J.E., Rinder, H.M., Civin, C., Cheng, L., et al. Cotransplantation of human mesenchymal stem cells enhances human myelopoiesis and megakaryocytopoiesis in NOD/SCID mice. Exp Hematol 31 (2003), 413–420.
10. [10] Maitra, B., Szekely, E., Gjini, K., Laughlin, M.J., Dennis, J., Haynesworth, S.E., et al. Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplant 33 (2004), 597–604.
11. [11] Noort, W.A., Kruisselbrink, A.B., in't Anker, P.S., Kruger, M., van Bezooijen, R.L., de Paus, R.A., et al. Mesenchymal stem cells promote engraftment of human umbilical cord blood-derived CD34(+) cells in NOD/SCID mice. Exp Hematol 30 (2002), 870–878.
12. [12] Polchert, D., Sobinsky, J., Douglas, G., Kidd, M., Moadsiri, A., Reina, E., et al. IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol 38 (2008), 1745–1755.
13. [13] Higgins, J., Deeks, J., Selecting studies and collecting data. Chapter 7 Higgins, J.P.T., Green, S., (eds.) Cochrane handbook for systematic reviews of interventions, version 5.1, 2011, The Cochrane Collaboration Chapter 7.
14. [14] Higgins, J., Altman, D., Sterne, J., Assessing risk of bias in included studies. Chapter 8 Higgins, J.P.T., Green, S., (eds.) Cochrane handbook for systematic reviews of interventions, version 5.1, 2011, The Cochrane Collaboration Chapter 8.
15. [15] Szydlo, R., Statistical evaluation of HSCT data. Chapter 21 Apperley, J., Carreras, E., Gluckman, E., Masszi, T., (eds.) The EBMT-ESH handbook, 6th ed, 2012, Haematopoietic Stem Cell Transplantation Chapter 21.
16. [16] Locatelli, F., Lucarelli, B., Merli, P., Current and future approaches to treat graft failure after allogeneic hematopoietic stem cell transplantation. Expert Opin Pharmacother 15 (2014), 23–36.
17. [17] Glucksberg, H., Storb, R., Fefer, A., Buckner, C.D., Neiman, P.E., Clift, R.A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 18 (1974), 295–304.
18. [18] Filipovich, A.H., Weisdorf, D., Pavletic, S., Socie, G., Wingard, J.R., Lee, S.J., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 11 (2005), 945–956.
19. [19] Jagasia, M.H., Greinix, H.T., Arora, M., Williams, K.M., Wolff, D., Cowen, E.W., et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 21 (2015), 389–401 e1.
20. [20] Shulman, H.M., Sullivan, K.M., Weiden, P.L., McDonald, G.B., Striker, G.E., Sale, G.E., et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 69 (1980), 204–217.
21. [21] Review manager (RevMan) [computer program]. Version 5.3. 2014, The Nordic Cochrane Centre TCC, The Cochrane Collaboration, Copenhagen.
22. [22] Hozo, S.P., Djulbegovic, B., Hozo, I., Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol, 5, 2005, 13.
23. [23] Ball, L.M., Bernardo, M.E., Roelofs, H., Lankester, A., Cometa, A., Egeler, R.M., et al. Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood 110 (2007), 2764–2767.
24. [24] Baron, F., Lechanteur, C., Willems, E., Bruck, F., Baudoux, E., Seidel, L., et al. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Biol Blood Marrow Transplant 16 (2010), 838–847.
25. [25] Bernardo, M.E., Ball, L.M., Cometa, A.M., Roelofs, H., Zecca, M., Avanzini, M.A., et al. Co-infusion of ex vivo-expanded, parental MSCs prevents life-threatening acute GVHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation. Bone Marrow Transplant 46 (2011), 200–207.
26. [26] Lee, S.H., Lee, M.W., Yoo, K.H., Kim, D.S., Son, M.H., Sung, K.W., et al. Co-transplantation of third-party umbilical cord blood-derived MSCs promotes engraftment in children undergoing unrelated umbilical cord blood transplantation. Bone Marrow Transplant 48 (2013), 1040–1045.
27. [27] Liu, K., Chen, Y., Zeng, Y., Xu, L., Liu, D., Chen, H., et al. Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: a randomized, controlled clinical study. Stem Cells Dev 20 (2011), 1679–1685.
28. [28] Macmillan, M.L., Blazar, B.R., DeFor, T.E., Wagner, J.E., Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: results of a phase I-II clinical trial. Bone Marrow Transplant 43 (2009), 447–454.
29. [29] Ning, H., Yang, F., Jiang, M., Hu, L., Feng, K., Zhang, J., et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia 22 (2008), 593–599.
30. [30] Wu, K.H., Sheu, J.N., Wu, H.P., Tsai, C., Sieber, M., Peng, C.T., et al. Cotransplantation of umbilical cord-derived mesenchymal stem cells promote hematopoietic engraftment in cord blood transplantation: a pilot study. Transplantation 95 (2013), 773–777.
31. [31] Wu, K.H., Tsai, C., Wu, H.P., Sieber, M., Peng, C.T., Chao, Y.H., Human application of ex vivo expanded umbilical cord-derived mesenchymal stem cells: enhance hematopoiesis after cord blood transplantation. Cell Transplant 22 (2013), 2041–2051.
32. [32] Guo, M., Sun, Z., Sun, Q.Y., Han, Q., Yu, C.L., Wang, D.H., et al. A modified haploidentical nonmyeloablative transplantation without T cell depletion for high-risk acute leukemia: successful engraftment and mild GVHD. Biol Blood Marrow Transplant 15 (2009), 930–937.
33. [33] Lazarus, H.M., Koc, O.N., Devine, S.M., Curtin, P., Maziarz, R.T., Holland, H.K., et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 11 (2005), 389–398.
34. [34] Le Blanc, K., Samuelsson, H., Gustafsson, B., Remberger, M., Sundberg, B., Arvidson, J., et al. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 21 (2007), 1733–1738.
35. [35] Zhang, X., Li, J.Y., Cao, K., Lu, H., Hong, M., Qian, S., et al. Cotransplantation of HLA-identical mesenchymal stem cells and hematopoietic stem cells in Chinese patients with hematologic diseases. Int J Lab Hematol 32 (2010), 256–264.
36. [36] Wu, Y., Wang, Z., Cao, Y., Xu, L., Li, X., Liu, P., et al. Cotransplantation of haploidentical hematopoietic and umbilical cord mesenchymal stem cells with a myeloablative regimen for refractory/relapsed hematologic malignancy. Ann Hematol 92 (2013), 1675–1684.
37. [37] Lee, S.T., Jang, J.H., Cheong, J.W., Kim, J.S., Maemg, H.Y., Hahn, J.S., et al. Treatment of high-risk acute myelogenous leukaemia by myeloablative chemoradiotherapy followed by co-infusion of T cell-depleted haematopoietic stem cells and culture-expanded marrow mesenchymal stem cells from a related donor with one fully mismatched human leucocyte antigen haplotype. Br J Haematol 118 (2002), 1128–1131.
38. [38] von Bonin, M., Kiani, A., Platzbecker, U., Schetelig, J., Holig, K., Oelschlagel, U., et al. Third-party mesenchymal stem cells as part of the management of graft-failure after haploidentical stem cell transplantation. Leuk Res 33 (2009), e215–17.
39. [39] Abecasis, M., Lobato, C., Ferreira, I., Arsenio, A., Teixeira, G., Miranda, N., et al. A potential role for mesenchymal stem cells in allogeneic bone marrow transplantation for familial haemophagocytic lymphohistiocytosis. Bone Marrow Transpl, 45, 2010, S327.
40. [40] Astrelina, T., Yakovleva, M., Shakhpazyan, N., Gomzyakov, A., Novoselova, N., Lazebnik, B., et al. The application of human mesenchymal stem cells in clinical practice. Bone Marrow Transpl, 47, 2012, S178.
41. [41] Ball, L.M., Bernardo, M.E., Van Tol, M.J.D., Roelofs, H., Zwaginga, J.J., Locatelli, F., et al. Multiple infusions of haploidentical mesenchymal stromal cells are not immunogenic in children undergoing myeloablative stem cell transplantation. Bone Marrow Transpl, 45, 2010, S382.
42. [42] Armstrong, R., Waters, E., Doyle, J., Reviews in health promotion and public health. Chapter 21 Higgins, J.P.T., Green, S., (eds.) Cochrane handbook for systematic reviews of interventions version 510, 2011, The Cochrane Collaboration updated March 2011; Chapter 21 http://wwwcochrane-handbookorg [accessed 14.05.15].
43. [43] Balshem, H., Helfand, M., Schunemann, H.J., Oxman, A.D., Kunz, R., Brozek, J., et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 64 (2011), 401–406.
44. [44] Hrobjartsson, A., Emanuelsson, F., Skou Thomsen, A.S., Hilden, J., Brorson, S., Bias due to lack of patient blinding in clinical trials. A systematic review of trials randomizing patients to blind and nonblind sub-studies. Int J Epidemiol 43 (2014), 1272–1283.
45. [45] Wood, L., Egger, M., Gluud, L.L., Schulz, K.F., Juni, P., Altman, D.G., et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 336 (2008), 601–605.
46. [46] Dubben, H.H., Beck-Bornholdt, H.P., Systematic review of publication bias in studies on publication bias. BMJ 331 (2005), 433–434.
47. [47] Le Blanc, K., Frassoni, F., Ball, L., Locatelli, F., Roelofs, H., Lewis, I., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371 (2008), 1579–1586.
48. [48] Galipeau, J., The mesenchymal stromal cells dilemma—does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road?. Cytotherapy 15 (2013), 2–8.
49. [49] Ringden, O., Mesenchymal stromal cells as first-line treatment of graft failure after hematopoietic stem cell transplantation. Stem Cells Dev 18 (2009), 1243–1246.
50. [50] Cutler, A., Girdlestone, J., Hopewell, S., Stanworth, S., Doree, C., Dazzi, F., et al. Mesenchymal stromal cells (MSC) for treating immune-mediated inflammation post-transplantation an in autoimmunity (Protocol). Cochrane Database Syst Rev(5), 2012 CD009768; doi:10.1002/14651858CD009768.
51. [51] Ito, S., Barrett, A.J., Dutra, A., Pak, E., Miner, S., Keyvanfar, K., et al. Long term maintenance of myeloid leukemic stem cells cultured with unrelated human mesenchymal stromal cells. Stem Cell Res 14 (2015), 95–104.
52. [52] Vianello, F., Dazzi, F., Mesenchymal stem cells for graft-versus-host disease: a double edged sword?. Leukemia 22 (2008), 463–465.
53. [53] Lalu, M.M., McIntyre, L., Pugliese, C., Fergusson, D., Winston, B.W., Marshall, J.C., et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS ONE, 7, 2012, e47559.